VIB4920 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sjögren's Syndrome
Conditions
Sjögren's Syndrome
Trial Timeline
Dec 9, 2019 → Mar 10, 2023
NCT ID
NCT04129164About VIB4920 + Placebo
VIB4920 + Placebo is a phase 2 stage product being developed by Amgen for Sjögren's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04129164. Target conditions include Sjögren's Syndrome.
What happened to similar drugs?
0 of 8 similar drugs in Sjögren's Syndrome were approved
Approved (0) Terminated (1) Active (7)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04129164 | Phase 2 | Completed |
| NCT04163991 | Phase 2 | Completed |
Competing Products
20 competing products in Sjögren's Syndrome